This trial tests whether adding radiation to standard immunotherapy improves outcomes for patients with metastatic renal cell cancer.
- Stage III Renal Cell Carcinoma
- Unresectable Renal Cell Carcinoma
- Stage IV Renal Cell Carcinoma
- Kidney Cancer
1 Primary · 9 Secondary · Reporting Duration: From randomization to last follow-up, up to 8 years
Awards & Highlights
2 Treatment Groups
Arm I (standard of care immunotherapy)
1 of 2
Arm II (SABR, standard of care immunotherapy)
1 of 2
240 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic Ablative Radiotherapy · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are new participants being accepted into this research trial?
"According to the data on clinicaltrials.gov, this clinical trial is looking for subjects as we speak. The study was first posted on 6/30/2022 and updated just last week on 7/29/2022." - Anonymous Online Contributor
How many people fit the requirements to be in this clinical trial?
"That is correct. The clinicaltrial.gov website lists this trial as currently open and recruiting patients. This study was first posted on June 30th, 2022 and was last updated on July 29th, 2022. There are 5 different sites enrolling a total of 240 participants." - Anonymous Online Contributor
In how many different healthcare facilities is this research project being conducted presently?
"The trial is currently running at 5 locations, which include the Carle Cancer Institute in Mattoon, Carle Physician Group-Mattoon/Charleston in Danville, and Carle on Vermilion in Effingham." - Anonymous Online Contributor
Has Stereotactic Ablative Radiotherapy undergone regulatory approval by the FDA?
"There is only some data supporting the safety of Stereotactic Ablative Radiotherapy, as this treatment is still in Phase 2 clinical trials. This means that while there have been no reports of serious adverse effects, it is unclear whether or not the treatment is effective." - Anonymous Online Contributor